REMARKS

Reconsideration and withdrawal of the assertion in the October 31, 2002 Office Communication that Applicants have not been fully responsive to the February 21, 2002 Office Action are respectfully requested in view of the amendments and remarks herewith.

Claim 30 provides

> 30. An immunological, immunogenic or vaccine composition against *Cryptosporidium parvum*, which comprises a first antigen comprising a P21 or Cp23 antigen or an epitope thereof or a first vector that expresses the first antigen and a second antigen comprising Cp15/60 antigen or epitope thereof or the first vector wherein the first vector expresses both the first and second antigens or a second vector that expresses the second antigen, and a pharmaceutically acceptable vehicle.

As can be seen from claim 30, the **first and second enteric pathogens of claim 1 NEED NOT** be different pathogens. That is, as shown by claim 30, **the first and second enteric pathogens of claim 1 CAN BE THE SAME**; namely, *Cryptosporidium parvum*; *see also* claim 36. That is, the requirement for an election of a second enteric antigen in the February 21, 2002 Office Action, it is respectfully submitted, should have included the possibility of Applicants electing an antigen of *Cryptosporidium parvum* as the second antigen. Accordingly, claim 1 is amended to clarify the situation, based on the text throughout the application and the original claims, including original claims 30 and 36. No new matter is added.

Moreover, it is respectfully asserted that Applicants, in the August 21, 2002 Amendment, sought to elect the subject matter of claim 30 wherein the species is bovine, the first antigen is P21, the second antigen is Cp 15/60 and the presentation of of the composition is in antigen form, so as to be fully responsive to the February 21, 2002 Office Action.

To further assist in the appreciation of the subject matter claimed and elected, with traverse, new claim 56 is presented herewith, which is based on original claim 30 and states:

> 56. (New) An immunological, immunogenic or vaccine composition against Cryptosporidium *parvum*, which comprises a first antigen comprising a P21 antigen or an epitope thereof and a second antigen comprising Cp15/60 antigen or epitope thereof, and a pharmaceutically acceptable vehicle.

Claim 56 is within the election and does not present any new matter. Any fee occasioned by this paper or any overpayment may be charged or credited to Deposit Account No. 50-0320.

If, with the herein clarification of the nature of claim 1 vis-à-vis claim 30, there is a need for a further election from between wherein the first and second enteric pathogens are the same,

namely, *Cryptosporidium parvum*, or are different, namely wherein the first enteric pathogen is *Cryptosporidium parvum* and the second enteric pathogen is a different pathogen, then as shown by the herein text, Applicants are electing the Group wherein the first and second enteric pathogens are the same, namely, *Cryptosporidium parvum*.

As a traverse, the remarks of the August 21, 2002 Amendment are hereby incorporated herein by reference and it is nonetheless respectfully asserted that there is no undue or serious burden upon the Examiner searching all of *Cryptosporidium parvum*, *E. coli*, rotavirus, coronavirus, *Clostridium* species and mixtures thereof as the second pathogen, as a unifying feature is *Cryptosporidium parvum* as the first pathogen.

In view of the above, reconsideration and withdrawal of the Requirement for Restriction and the assertion that the August 21, 2002 Amendment was non-responsive are respectfully requested.

REQUEST FOR INTERVIEW

If any issue remains as an impediment to further examination and/or allowance, an interview with the is respectfully requested, prior to issuance of any paper other than a first Office Action on the merits and/or a Notice of Allowance; and, the Examiner is respectfully requested to contact the undersigned to arrange a mutually convenient time and manner for such an interview.

CONCLUSION

In view of the remarks and amendments herewith and those of record, the application is in condition for allowance, or at the very least a first Office Action on the merits. Favorable reconsideration of the application and prompt issuance of a Notice of Allowance, or an interview at a very early date with a view to resolving any issue that is an impediment to issuing a first Office Action and/or placing the application in condition for allowance, are earnestly solicited. The undersigned looks forward to hearing favorably from the Examiner at an early date.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP
Attorneys for Applicants

By: Thomas J. Kowalski

Thomas J. Kowalski, Reg. No. 32,147
Angela M. Nigro, Reg. No. 51,107
Tel (212) 588-0800, Fax (212) 588-0500

APPENDIX: MARKED VERSION OF AMENDMENT

Kindly amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents as follows:

IN THE CLAIMS:

Please amend the claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, to read as follows:

1. (Twice Amended) A combined immunological, immunogenic or vaccine composition comprising a first antigen or epitope of interest from a first enteric pathogen comprising *Cryptosporidium* and/or a first vector that expresses the first antigen or epitope of interest, and a second antigen or epitope of interest from a second enteric pathogen and/or the first vector that expresses the first antigen or epitope of interest also expresses the second antigen or epitope of interest and/or a second vector that expresses the second antigen or epitope of interest, and a pharmaceutically acceptable vehicle wherein the first and second enteric pathogens can be the same enteric pathogen or different enteric pathogens.

Please add the following new claim:

--56. (New) An immunological, immunogenic or vaccine composition against Cryptosporidium *parvum*, which comprises a first antigen comprising a P21 antigen or an epitope thereof and a second antigen comprising Cp15/60 antigen or epitope thereof, and a pharmaceutically acceptable vehicle.--